PRP Kits and Systems

Wholesale PRP Kits for Licensed Practices

Six kit configurations across three draw volumes, supplied to NPI-verified practices. The selection notes below are the parameters that distinguish one system from another, drawn from the peer-reviewed literature rather than from marketing.

Gravity separation is what these kits use

Every kit in this line is a double-tube gravity-separation system. Whole blood is drawn into the tube, spun, and the separated fraction is decanted through the second chamber without opening the assembly to room air.

That closed architecture is the practical default for most clinic settings. It is easier to standardize across operators and imposes fewer procedural requirements for maintaining sterility than an open transfer.

The three volumes exist for different draw sizes

Kits are supplied in 12 mL, 15 mL and 30 mL formats. The volume determines the whole-blood draw the tube is designed to accept, not the concentration of the resulting preparation.

Practices running a single protocol usually standardize on one volume and hold a bulk tube pack against it. Practices running both small-field and large-field procedures more often carry two.

Two specialty kits carry an added component

The Biotin-PRP kit includes a biotin complex and the HA-PRP kit includes hyaluronic acid, each supplied within the kit rather than added at the point of use.

Both remain gravity-separation kits in the same family. The added component is a formulation difference, and the prescriber determines whether a given configuration suits the procedure.

Leukocyte content is a selection decision, not a quality ranking

Preparations are commonly described as leukocyte-rich or leukocyte-poor depending on how much of the buffy coat is retained. Both are used clinically, and the published classification systems list them as distinct categories rather than as better and worse.

This is worth settling before you standardize, because it is the parameter that most affects whether results are comparable between two kits.

Anticoagulant and spin protocol drive the variability

Acid citrate dextrose and sodium citrate are the anticoagulants in common use, and each affects the pH of the final concentrate. Heparin is generally avoided because of its inhibitory effect on platelet aggregation.

Spin speed and duration interact to determine platelet recovery and how much of the leukocyte fraction carries over. Single-spin and double-spin protocols produce materially different preparations from the same blood volume.

The device and the preparation are regulated separately

A PRP preparation device is regulated as a device in its own right, separately from the autologous preparation a clinician produces with it. Where a system carries FDA 510(k) clearance, that clearance names specific intended uses and does not extend across every potential application area.

Confirming that the cleared intended use of a system aligns with the procedures a practice performs sits with the clinician. We supply the documentation to support that review.

What to confirm before you order

The items below are what a rigorous procurement review asks for, and what we provide on request for any kit in this line.

  • The intended use statement for the system, and its clearance number where one applies.
  • Lot-level traceability documentation for the kit as supplied.
  • Sterility and biocompatibility testing certificates.
  • The anticoagulant specification and the validated spin protocol for the kit.
  • Storage conditions, and whether any component requires cold chain.

Access is gated

Kit specifications, documentation and wholesale terms are released to NPI-verified practices. Apply for access or request pricing and we will route the documentation with the quote.

References

  1. [1]Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018;4(1):18-24. PMC
  2. [2]Everts PA, et al. Platelet-Rich Plasma: A Short Overview of Certain Bioactivities and Clinical Implications in Regenerative Medicine. J Clin Med. 2017;6(5):55. PMC
  3. [3]DeLong JM, et al. Platelet-Rich Plasma: The PAW Classification System. Arthroscopy. 2012;28(7):998-1009. PMC
  4. [4]Mishra A, et al. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2010;11(2):185-190. PMC